多参数流式细胞术检测微小残留病在初诊多发性骨髓瘤中的作用:106例患者分析
单中心回顾性分析2013年6月至2015年6月106例连续收治的初诊多发性骨髓瘤患者,采用多参数流式细胞术检测微小残留病。48例(45.3%)达MRD阴性,中位达阴性时间3个月;ASCT患者转阴率62.2%高于非ASCT患者36.2%(P=0.011)。MRD为PFS和OS的独立预后因素,转阴的高危细胞遗传学患者预后与标危转阴患者相近。
要点
- 106例初诊MM患者中48例(45.3%)经MFC检测达MRD阴性,中位达阴性时间3个月。
- ASCT患者MRD转阴率62.2%高于非ASCT患者36.2%(χ²=6.536,P=0.011)。
- MRD是PFS(HR=0.133,95%CI 0.062~0.288)和OS(HR=0.156,95%CI 0.050~0.484)的独立预后因素。
核心结论
- MFC检测的MRD转阴在ASCT患者中更常见,MRD是MM独立预后因素,可据此进行预后分层。
- MRD转阴的细胞遗传学高危患者预后与标危转阴患者相近。
- 作者认为MFC检测MRD值得在临床推广应用。
研究设计与样本
- 单中心回顾性分析2013年6月至2015年6月106例连续收治的初诊MM患者,均采用MFC检测MRD。
主要发现
- 106例中48例(45.3%)MRD转阴,中位达MRD阴性时间3个月。
- ASCT患者MRD转阴率62.2% vs 非ASCT患者36.2%(χ²=6.536,P=0.011)。
- 48例CR患者中7例(14.6%)MRD持续阳性,其中5例疾病进展、3例死亡;中位PFS 19个月,中位OS 28个月,均短于MRD转阴CR患者(P<0.05)。
- 中位随访38个月,MRD转阴患者中位PFS未达到 vs MRD阳性患者17个月(P<0.001),中位OS均未达到(P<0.001)。
- 按MRD水平≥1%、0.1%~<1%、0.01%~<0.1%和阴性分组,随MRD水平降低PFS及OS有逐渐延长趋势。
关键数值与推荐
- 多因素分析:MRD对PFS的HR=0.133(95%CI 0.062~0.288),P<0.001;对OS的HR=0.156(95%CI 0.050~0.484),P=0.001。
- 按MRD和细胞遗传学分为4组,MRD转阴的高危患者PFS及OS明显好于MRD阳性的高危患者(P<0.05),与MRD转阴的标危患者相近(P>0.05)。
临床怎么用
- 作者认为MFC检测MRD值得在临床推广应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To assess the feasibility and prognostic value of the minimal residual disease (MRD) evaluated by multiparameter flow cytometry (MFC) in the newly diagnosed multiple myeloma (MM) patients of China. Methods: Clinical data of 106 consecutively newly diagnosed MM patients with MRD data were retrospectively analyzed in a single center in China from June 2013 to June 2015. Results: ① Of 106 patients, 48 (45.3%) achieved MRD negativity. The median time to MRD-negative was 3 months. More patients undergoing autologous stem cell transplantation (ASCT) achieved MRD negativity compared with non-ASCT patients (62.2% vs 36.2%, χ(2)=6.536, P=0.011). ② Of 48 patients in complete remission (CR), 7 (14.6%) was MRD positive, 5 of them showed disease progression (PD) during the follow-up, and 3 died. The median progression free survival (PFS) was 19 months, and the median overall survival (OS) was 28 months, both were significantly shorter than the CR patients with MRD-negative (P<0.05). ③At a median follow-up of 38 months, MRD-negative patients showed significantly superior outcomes compared with MRD positive ones, the PFS was not reach versus 17 months and the OS was not reach for both (P<0.001). Patients were grouped into 4 categories according to their MRD levels: 1% or higher, 0.1% to less than 1%, 0.01% to less than 0.1%, or negative. It showed that the outcomes (PFS and OS) tended to be improved along with the tumor depletion. ④ Multivariate prognostic analysis showed that MRD was a powerful independent prognostic factor for PFS[HR=0.133 (95% CI 0.062-0.288) , P<0.001] and OS[HR=0.156 (95% CI 0.050-0.484) , P=0.001]. According to MRD and cytogenetics, the patients were classified into 4 groups. High risk patients with MRD negative presented a significantly better outcome than high risk patients with MRD-positive, and a similar one to the standard risk patients with MRD-negative. Conclusions: MRD negativity by MFC was more popular in MM patients undergoing ASCT. MRD was an independent prognostic factor in MM. And the prognosis of MM patients can be stratified according to the level of MRD. MRD-negative patients with high risk cytogenetics presented a similar outcome to the standard risk ones. MRD by MFC should therefore be considered more widely applied in the clinic. 目的: 探讨多参数流式细胞术(MFC)检测微小残留病(MRD)在我国初诊多发性骨髓瘤(MM)患者中的可行性及其预后意义。 方法: 回顾性分析2013年6月至2015年6月106例采用MFC进行MRD检测连续收治的初诊MM患者的临床资料。 结果: ①106例患者中48例(45.3%)MRD转为阴性,中位达MRD阴性时间为3个月。接受自体造血干细胞移植(ASCT)患者MRD转阴率显著高于未接受ASCT患者(62.2%对36.2%,χ(2)=6.536,P=0.011)。②48例完全缓解(CR)患者中7例(14.6%)MRD持续阳性,这7例患者中5例已疾病进展,中位无进展生存(PFS)时间为19个月,3例死亡,中位总生存(OS)时间为28个月,MRD持续阳性CR患者的PFS及OS时间均明显短于MRD转阴CR患者(P值均<0.05)。③中位随访38个月,MRD转阴患者的预后显著优于阳性患者,二者中位PFS时间分别为未达到和17个月(P<0.001),中位OS均未达到(P<0.001)。根据MRD水平将患者分为四组:≥1%、0.1%~<1%、0.01%~<0.1%和阴性,结果显示随着MRD水平的降低,患者PFS及OS时间有逐渐延长趋势。④多因素分析显示,MRD是影响MM患者PFS[HR=0.133(95% CI 0.062~0.288),P<0.001]和OS[HR=0.156(95% CI 0.050~0.484),P=0.001]的独立预后因素。根据MRD、细胞遗传学情况将患者分为4组,结果显示MRD转阴的高危患者预后(PFS及OS)明显好于MRD阳性的高危患者(P<0.05),而与MRD转阴的标危患者预后相近(P>0.05)。 结论: ASCT患者中MFC检测的MRD转阴率更高。MRD是MM患者的独立预后因素,根据MRD水平可以对患者预后进行分层。MRD转阴的细胞遗传学高危患者的预后与标危患者相近。MFC检测MRD值得在临床推广应用。.
引用
- Deng SH, Xu Y, Sui WW, et al. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29779345. doi:10.3760/cma.j.issn.0253-2727.2018.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。